Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Adolor ADLR -- Ignore unavailable to you. Want to Upgrade?

To: Jack Hartmann who wrote (1)	1/26/2009 4:27:22 PM
From: Jack Hartmann	Respond to of 2

Oct 28, 2008 (BUSINESS WIRE) -- Adolor Corporation (ADLR:ADLR News , chart , profile , more Last: Delayed quote dataAdd to portfolio Analyst Create alert Insider Discuss Financials Sponsored by: ADLR, , ) today reported financial results for the three and nine months ended September 30, 2008. For the three months ended September 30, 2008, the company reported a net loss of $13.3 million, or $0.29 per basic and diluted share, compared to a net loss of $13.5 million, or $0.29 per basic and diluted share, in the three months ended September 30, 2007. For the nine-month period ended September 30, 2008, the company reported a net loss of $14.8 million, or $0.32 per basic and diluted share, compared to a net loss of $38.3 million, or $0.83 per basic and diluted share, for the same period in 2007. Revenues were approximately $7.9 million and $1.8 million for the three months ended September 30, 2008 and 2007, respectively, and were approximately $41.0 million and $5.4 million for the nine months ended September 30, 2008 and 2007, respectively. The increase in revenues in 2008 over 2007 principally reflect a $20.0 million milestone payment received from Glaxo in conjunction with FDA approval of Entereg(R) (alvimopan) for POI and contract revenues associated with the Pfizer collaboration. Revenues in the quarter ended September 30, 2008 also include net product sales of Entereg of approximately $168,000. Total net shipments of Entereg through September 30, 2008 were approximately $598,000. "The third quarter was highlighted by the launch of Entereg with our partner, Glaxo," said Michael R. Dougherty, president and chief executive officer of Adolor Corporation. "Initial launch activities have included the registration of hospitals under the E.A.S.E.(TM) Program, now totaling approximately 900 hospitals. In the coming months, a number of these institutions will be considering the inclusion of Entereg on hospital formularies."